文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

维生素C、硫胺素和糖皮质激素代谢复苏治疗脓毒症早期结局:ORANGES试验

Outcomes of Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in the Early Treatment of Sepsis: The ORANGES Trial.
PubMed 文献 · Chest · 2020-03-17
一句话结论在脓毒症和脓毒性休克ICU患者中,静脉维生素C、硫胺素和氢化可的松联合治疗显著缩短了休克逆转时间(27±22 vs 53±38小时,P<.001),但SOFA评分变化及死亡率等无显著差异。

ORANGES试验是一项随机、双盲、安慰剂对照试验,于2018年2月至2019年6月纳入137例收入ICU的脓毒症和脓毒性休克患者,随机分为治疗组(n=68)和对照组(n=69),评估氢化可的松、维生素C、硫胺素(HAT)联合治疗方案。主要结局为休克逆转和SOFA评分变化。结果显示HAT组需要血管升压药的时间显著短于对照组(27±22 vs 53±38小时,P<.001),但SOFA评分变化组间无显著差异(3(1-6)vs 2(0-4),P=.17)。ICU死亡率、住院死亡率、ICU和住院时间、无呼吸机天数及降钙素原清除率均无显著差异。作者认为HAT联合治疗显著缩短了休克逆转时间,但需进一步研究确认并评估潜在死亡率获益。

要点

  • 在脓毒症和脓毒性休克ICU患者中,HAT组需要血管升压药的时间为27±22小时,显著短于对照组的53±38小时(P<.001)。
  • HAT组与对照组SOFA评分变化无显著差异:3(1-6)vs 2(0-4),P=.17。
  • ICU死亡率、住院死亡率、ICU和住院时间、无呼吸机天数及降钙素原清除率组间均无显著差异。
  • 作者认为HAT联合治疗显著缩短了休克逆转时间,但需进一步研究确认并评估潜在死亡率获益。

适用人群与场景

  • 收入ICU的脓毒症和脓毒性休克患者。

处置流程与药物剂量

  • HAT治疗方案为静脉维生素C、硫胺素和氢化可的松联合治疗;原文未写明具体剂量、给药频次和疗程。

研究设计与关键结果

  • 研究类型:随机、双盲、安慰剂对照试验;样本量137例,治疗组n=68,对照组n=69;人群为收入ICU的脓毒症和脓毒性休克患者;干预为HAT联合治疗,对照为安慰剂。
  • 主要终点:需要血管升压药的时间HAT组27±22小时 vs 对照组53±38小时,P<.001;SOFA评分变化HAT组3(1-6)vs 对照组2(0-4),P=.17。
  • 关键次要终点:28天死亡率、ICU死亡率、住院死亡率、降钙素原清除率、住院时间、ICU时间、无呼吸机天数组间均无显著差异。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,静脉维生素C、硫胺素和氢化可的松联合治疗显著缩短了脓毒症和脓毒性休克患者的休克逆转时间,但需进一步研究确认这些发现并评估潜在的死亡率获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Sepsis is a major public health burden resulting in 25% to 30% in-hospital mortality and accounting for over 20 billion dollars of US hospital costs.

RESEARCH QUESTION: Does hydrocortisone, ascorbic acid, thiamine (HAT) therapy improve clinical outcomes in sepsis and septic shock?

STUDY DESIGN AND METHODS: This was a randomized, double-blinded, placebo-controlled trial conducted from February 2018 to June 2019, assessing an HAT treatment bundle for the management of septic and septic shock patients admitted to an ICU. The primary outcomes were resolution of shock and change in Sequential Organ Failure Assessment (SOFA) score. Secondary outcomes included 28-day mortality, ICU mortality, hospital mortality, procalcitonin clearance (PCT-c), hospital length of stay (LOS), ICU LOS, and ventilator-free days.

RESULTS: One hundred thirty-seven patients were randomized to the treatment group (n = 68) and comparator group (n = 69), respectively, with no significant differences in baseline characteristics. A statistically significant difference was found in the time patients required vasopressors, indicating quicker reversal of shock in the HAT group compared with the comparator group (27 ± 22 vs 53 ± 38 hours, P < .001). No statistically significant change in SOFA score was found between groups 3 (1 - 6) vs 2 (0 - 4), P = .17. No significant differences were found between study arms in ICU and hospital mortality, ICU and hospital LOS, ventilator free days, and PCT-c.

INTERPRETATION: Our results suggest that the combination of IV ascorbic acid, thiamine, and hydrocortisone significantly reduced the time to resolution of shock. Additional studies are needed to confirm these findings and assess any potential mortality benefit from this treatment.

TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT03422159; URL: www.clinicaltrials.gov.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Iglesias J, Vassallo AV, Patel VV, et al. Outcomes of Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in the Early Treatment of Sepsis: The ORANGES Trial. Chest. 2020. PMID: 32194058. doi:10.1016/j.chest.2020.02.049

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。